LENZ THERAPEUTICS, INC. Restructuring Costs and Asset Impairment Charges
LENZ THERAPEUTICS, INC. (LENZ) reported Restructuring Costs and Asset Impairment Charges of $5.30 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2023-11-13
- LENZ THERAPEUTICS, INC. restructuring costs and asset impairment charges for the quarter ending 2023-09-30 was $5.30M.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month | Restructuring Costs and Asset Impairment Charges 6 month | Restructuring Costs and Asset Impairment Charges 9 month |
|---|---|---|---|
| 2023-09-30 | $5.30M 10-Q · filed 2023-11-13 | $6.80M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $1.10M 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |